NIP
KYMR icon

Nicholas Investment Partners’s Kymera Therapeutics KYMR Stock Holding History

Nicholas Investment Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.26M Buy
54,569
+27,222
+100% +$2.34M 0.35% 105
2026
Q1 		$2.28M Sell
27,347
-28,441
-51% -$2.25M 0.16% 154
2025
Q4 		$4.34M Buy
55,788
+3,163
+6% +$214K 0.32% 119
2025
Q3 		$2.98M Buy
+52,625
New +$2.37M 0.23% 145

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nicholas Investment Partners's KYMR Position: Q2 2026 in Review

Nicholas Investment Partners increased its Kymera Therapeutics (KYMR) stake by 100% in Q2 2026, buying an estimated $2.34M and bringing the position to 54,569 shares worth $6.26M. The position accounts for 0.35% of the portfolio, ranked #105.

Nicholas Investment Partners first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Nicholas Investment Partners held 54,569 shares of Kymera Therapeutics worth $6.26M as of Q2 2026.
  • Nicholas Investment Partners bought 27,222 Kymera Therapeutics shares in Q2 2026, an estimated $2.34M.
  • Kymera Therapeutics made up 0.35% of Nicholas Investment Partners's portfolio in Q2 2026, its #105 holding.
  • Nicholas Investment Partners first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.